This trial is examining the effectiveness of atezolizumab (Tecentriq) plus carboplatin (Paraplatin) and etoposide (Etopophos) with or without tiragolumab in patients with untreated extensive-stage small-cell lung cancer (ES-SCLC). The main outcomes that will be measured are progression-free survival (PFS) and overall survival (OS).
The details
Small cell lung cancer (SCLC) is an aggressive form of lung cancer. About 10-15% of lung cancers are SCLC. Standard care for SCLC is chemotherapy. Carboplatin and etoposide (CE) is a form of chemotherapy used in these patients. Atezolizumab is a monoclonal antibody (immune proteins) approved for the treatment of SCLC. It works by activating the immune system to attack and kill cancer cells. Tiragolumab is a new immune therapy that is under evaluation.
This trial is evaluating the effectiveness of atezolizumab and CE chemotherapy in combination with tiragolumab in patients with ES-SCLC. The main outcomes to be measured are PFS and OS.
Who are they looking for?
The trial is looking to recruit 400 patients with confirmed ES-SCLC. Patients must have no prior systemic (that enters the blood) treatment for ES-SCLC and must be treatment-free for 6 months if they have received treatment for limited-stage (LS) SCLC. Patients must have adequate organ and blood function.
Patients must not have cancer spread to the brain, a history of other cancers, autoimmune conditions, lung disease, infections (including HIV, hepatitis B, C), or previous immunotherapies.
How will it work
There are two groups involved in this trial. Group 1 will receive tiragolumab plus atezolizumab and CE. Tiragolumab will be given by intravenous (IV) infusion on day 1 of every 21-day cycle. Group 2 will receive atezolizumab and CE plus a placebo.
Patients will be followed up for PFS, OS, response rate, and side effects for up to 43 months.
